The Schizophrenia Phenotype in 22q11 Deletion Syndrome

2003/08/27 by Anne S. Bassett, Eva W.C. Chow, Philip AbdelMalik +4 · 28 citations
Biochemistry, Genetics and Molecular Biology · Neuroscience · #Congenital heart defects research #Genomic variations and chromosomal abnormalities #Williams Syndrome Research

paper · doi:10.1176/appi.ajp.160.9.1580

Abstract

OBJECTIVE: This study investigated the schizophrenia phenotype in 24 subjects with 22q11 deletion syndrome (22qDS) and schizophrenia (22qDS-schizophrenia), a rare but relatively homogenous genetic subtype of schizophrenia associated with a microdeletion on chromosome 22. Individuals with 22qDS are at genetically high risk for schizophrenia. METHOD: Standard measures of signs, symptoms, and course of schizophrenia were assessed in 16 adults with 22qDS-schizophrenia who did not meet criteria for mental retardation and in 46 adults with schizophrenia without evidence of 22qDS from a community familial sample. RESULTS: There were no significant differences in age at onset, lifetime or cross-sectional core positive and negative schizophrenic symptoms, or global functioning between the two groups of patients with schizophrenia. Patients with 22qDS-schizophrenia had higher excitement subscale scores and less lifetime substance use than the comparison patients with schizophrenia, but no significant differences in anxiety-depression symptom severity were found between the groups. CONCLUSIONS: These findings indicate that the core clinical schizophrenia phenotype would not distinguish individuals with a 22qDS subtype from those with schizophrenia who did not have the 22qDS subtype. The results provide further support for the utility of 22qDS-schizophrenia as a neurodevelopmental model of schizophrenia as well as support for prospective studies of individuals with 22qDS to help identify precursors of schizophrenia.

Cited by

• Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone.
• Population differences of chromosome 22q11.2 duplication structure predispose differentially to microdeletion and inversion
• The behavioural phenotype in velo‐cardio‐facial syndrome
• Clinical features of 78 adults with 22q11 Deletion Syndrome. [europepmc]
• COMT genetic variation confers risk for psychotic and affective disorders: a case control study. [europepmc]
• Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. [europepmc]
• Advances in white matter imaging: a review of in vivo magnetic resonance methodologies and their applicability to the study of development and aging. [europepmc]
• microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. [europepmc]
• Schizophrenia and 22q11.2 deletion syndrome. [europepmc]
• Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. [europepmc]
• Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. [europepmc]
• Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. [europepmc]
• 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. [europepmc]
• Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. [europepmc]
• The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. [europepmc]
• Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. [europepmc]
• The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. [europepmc]
• Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. [europepmc]
• The pattern of cortical dysfunction in a mouse model of a schizophrenia-related microdeletion. [europepmc]
• Neurocognitive development in 22q11.2 deletion syndrome: comparison with youth having developmental delay and medical comorbidities. [europepmc]
• Practical guidelines for managing adults with 22q11.2 deletion syndrome. [europepmc]
• Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. [europepmc]
• Developmental trajectories in 22q11.2 deletion. [europepmc]
• 22q11.2 deletion syndrome. [europepmc]
• Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion. [europepmc]
• Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. [europepmc]
• Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. [europepmc]
• Genome-wide Association Analysis of Parkinson's Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci. [europepmc]

Related

• A comprehensive overview of neuropsychiatric symptoms in adolescents with 22q11.2 deletion syndrome
• Development and evaluation of an educational resource for parents of children with 22q11.2 deletion syndrome about the psychiatric manifestations of the condition
• Analysis of 15q11.2 CNVs in an Indian population with schizophrenia
• Toward Reformulating the Diagnosis of Schizophrenia
• Analysis of copy number variations at 15 schizophrenia-associated loci